SecBot SecBot
8-K ·Filed Nov 4, 2026

HRMY

Harmony Biosciences Holdings, Inc.
BEARISH
Impact 5/10
Horizondays Processed12d 18h ago SEC0001104659-26-122377
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The EPS miss is severe, but revenue growth and reiterated guidance provide a floor. Watch for the ANDA litigation preliminary injunction ruling by Feb 14, 2027, and Phase 1b BP-205 data in Q1 2027 as key catalysts. The CEO transition is planned and not expected to alter strategy.

DirectionBearish
Confidencehigh
Horizondays

Price Chart

Loading chart...

Executive Summary

Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9M (+12% YoY), missing consensus of $272.1M, and GAAP diluted EPS of $0.81, well below the Street consensus of $1.47. Net income declined 5% YoY to $48.2M due to higher R&D milestone costs and new royalty charges. The company reiterated full-year WAKIX net revenue guidance of $1.0B-$1.04B and announced positive preliminary multiple-ascending dose data for its orexin agonist BP-205, supporting its best-in-class profile. CEO Jeffrey Dayno will retire effective January 1, 2027, with COO Peter Anastasiou succeeding him.

Key Financial Metrics

EPS
$0.81
est $1.47 · -44.9%
Revenue
$268.9M
est $272.1M · -1.2% · +12.3% YoY
Rating
miss
Guidance
$1.0B-$1.04B
maintained
Gross Margin
70%

Key Facts

  • Q3 2026 WAKIX net revenue $268.9M, +12% YoY from $239.5M, below $272.1M consensus
  • GAAP diluted EPS $0.81, down from $0.87 in Q3 2025, missing $1.47 consensus
  • Net income $48.2M, down 5% YoY from $50.9M
  • Cost of product sold 30% of revenue vs 25% a year ago, driven by new Novitium royalties
  • R&D expense $71.7M, +30% YoY, including a $25M MSN license milestone charge
  • Cash, cash equivalents and investments $1.05B, up from $882.5M at year-end 2025
  • Reiterated full-year 2026 WAKIX net revenue guidance of $1.0B-$1.04B
  • Preliminary BP-205 MAD data showed favorable safety, tolerability and PK profile; Phase 1b data expected Q1 2027
  • CEO Jeffrey Dayno to retire Dec 31, 2026; Peter Anastasiou to become CEO effective Jan 1, 2027
  • Preliminary injunction hearing in AET ANDA litigation scheduled for Jan 26, 2027, with ruling expected by Feb 14, 2027

Financial Impact

Q3 revenue $268.9M (+12% YoY), EPS $0.81 (-7% YoY), net income $48.2M (-5% YoY); EPS missed consensus by 45%

revenueepsnet incomecost of product soldR&D expense

Risk Factors

  • EPS miss of 45% vs consensus may pressure the stock near-term
  • Cost of product sold margin deterioration from new royalty obligations
  • Pending ANDA litigation outcome could impact WAKIX exclusivity beyond March 2030
  • CEO transition introduces execution risk, though described as planned

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
72% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-122377
Document: hrmy-20261104x8k.htm0001104659-26-122377
Document: hrmy-ex99d2.htm0001104659-26-122377
Document: 0001104659-26-122377-index-headers.html0001104659-26-122377
Document: 0001104659-26-122377-index.html0001104659-26-122377
Document: 0001104659-26-122377.txt0001104659-26-122377
8-K Data (Synthetic)0001104659-26-122377

Track record

20 reports on HRMY

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
  2. Nov 4, 202612d ago 8-K Bearish 5/10 Viewing No price data
  3. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $34.42 Now $32.96 +4.23% settles Dec 3
  4. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
  5. Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
  6. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
  7. Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
  8. Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
  9. Aug 4, 202614w ago 8-K Bullish 7/10 No price data
  10. Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026